Evidence map›Paper›PMID 37980961›Full record

ArticleToxicology and applied pharmacology2023

In vitro and in vivo approaches to assess atherosclerosis following exposure to low-dose mixtures of arsenic and cadmium.

Nivetha K Subramaniam, Natascha Gagnon, Kiran Makhani, Nikola Kukolj, Michael H Mouradian, Braeden H Giles, Harinee Srikannan, Victoria Fruh, Jaymie Meliker, Gregory A Wellenius and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Toxicology and applied pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Nivetha K SubramaniamDivision of Experimental Medicine, McGill University, Montreal, Quebec, Canada; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada. Electronic address: nivetha.subramaniam@mail.mcgill.ca.
Natascha GagnonLady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada. Electronic address: natascha.gagnon@ladydavis.ca.
Kiran MakhaniDivision of Experimental Medicine, McGill University, Montreal, Quebec, Canada; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada. Electronic address: kiran.makhani@mail.mcgill.ca.
Nikola KukoljDepartment of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada. Electronic address: nikola.kukolj@mail.mcgill.ca.
Michael H MouradianDepartment of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada. Electronic address: michael.mouradian@mail.mcgill.ca.
Braeden H GilesDepartment of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada. Electronic address: braeden.giles@mail.mcgill.ca.
Harinee SrikannanLady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada. Electronic address: harinee.srikannan@mail.mcgill.ca.
Victoria FruhDepartment of Environmental Health, Boston University School of Public Health, Boston, MA, USA. Electronic address: vfru1212@bu.edu.
Jaymie MelikerProgram in Public Health, Department of Family, Population, & Preventive Medicine, Stony Brook University, Stony Brook, NY, USA. Electronic address: jaymie.meliker@stonybrookmedicine.edu.
Gregory A WelleniusCenter for Climate and Health, Boston University School of Public Health, Boston, MA, USA. Electronic address: wellenius@bu.edu.
Koren K MannDivision of Experimental Medicine, McGill University, Montreal, Quebec, Canada; Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada. Electronic address: koren.mann@mcgill.ca.
Jewish General Hospital · CAMcGill University · CABoston University · USStony Brook University · US

Funding

Metal-nutrient mixtures in epidemiologic and toxicologic studies of cardiovascular diseaseR01ES030938 · NIEHS · STATE UNIVERSITY NEW YORK STONY BROOK · PI MELIKER, JAYMIE R · 2020 to 2022
$1.8M
NIEHS NIH HHS R01 ES030938
6 · The paper itself

Abstract

Worldwide, millions of people are co-exposed to arsenic and cadmium. Environmental exposure to both metals is linked with a higher risk of atherosclerosis. While studies have characterized the pro-atherosclerotic effects of arsenic and cadmium as single agents, little is known about the potential effects of metal mixtures, particularly at low doses. Here, we used a combination of in vitro and in vivo models to assess the effects of low-dose metals individually and as mixtures on early events and plaque development associated with atherosclerosis. In vitro, we investigated early pro-atherogenic changes in macrophages and endothelial cells with metal treatments. The combined cytotoxic effects of both metals at low concentrations were dose interactive, specifically, synergistic in macrophages, but antagonistic in endothelial cells. Despite this differential behavior across cell types, the mixtures did not initiate early pro-atherogenic events: neither reactive oxygen species generation in macrophages nor adhesion molecule expression on endothelial cells. In vivo, we utilized the well-characterized hyperlipidemic apolipoprotein E knock-out (ApoE

Indexed as

ArsenicAtherosclerosisPlaque, AtheroscleroticAnimalsApolipoproteins ECadmiumEndothelial CellsFemaleHumansMaleMetalsMiceApolipoproteins EArsenicCadmiumMetalsArsenicAtherosclerosisCadmiumLow-DoseMixtures

Identifiers

PMID37980961
PMCPMC11414205
OpenAlexW4388798994

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.